A novel maxizyme vector targeting a bcr-abl fusion gene induced specific cell death in Philadelphia chromosome-positive acute lymphoblastic leukemia [PDF]
Yasushi Soda
openalex +1 more source
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr‐Abl activation and of in vitro proliferation of Philadelphia‐positive acute lymphoblastic leukemia cells [PDF]
Srđan Verstovšek+12 more
openalex +1 more source
New treatment regimen for acute megakaryoblastic leukemia with BCR-ABL positive: case report and literature review [PDF]
Huafei Shen+4 more
openalex +1 more source
Durable responses to imatinib in patients with PDGFRB fusion gene–positive and BCR-ABL–negative chronic myeloproliferative disorders [PDF]
Marianna Dávid+23 more
openalex +1 more source
Preclinical Evaluation of a Novel Small Molecule Inhibitor of LIM Kinases (LIMK) CEL_Amide in Philadelphia-Chromosome Positive (BCR::ABL+) Acute Lymphoblastic Leukemia (ALL) [PDF]
Jeannig Berrou+14 more
openalex +1 more source
This symposium was dedicated to discussing BCR-ABL-positive chronic myeloid leukaemia (CML) and Philadelphia-positive acute lymphoblastic leukaemia (Ph+ALL).
Michele Baccarani+4 more
doaj
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors [PDF]
Simona Soverini+19 more
openalex +1 more source
Neue Ansätze des molekularen Targetings bei der Philadelphia-Chromosom-positiven Leukämie [PDF]
In Philadelphia Chromosome (Ph) positive ALL and CML the fusion between BCR and ABL leads to the BCR/ABL fusion proteins, which induces the leukemic phenotype because of the constitutive activation of multiple signaling pathways down-stream to the ...
Mian, Afsar Ali
core